PRESSEMITTEILUNGEN

Nyon, Switzerland (ots/PRNewswire) – Significantly lower proportion of subjects experiencing treatment failure whilst receiving LDX in the randomised withdrawal period, compared to those subjects receiving placebo.[1] Today, at the EUNETHYDIS 2nd International ADHD Conference, Shire AG , the global specialty biopharmaceutical company, presented results of the phase 3 study which demonstrated the long-term maintenance of [...]

Continue reading

Adhd, Adhd Children, Adverse Events, Attention Deficit Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder Adhd, Deficit Hyperactivity Disorder, Deficit Hyperactivity Disorder Adhd, Dr Jeffrey, Jeffrey Jonas, Ldx, Maintenance Therapy, Phase 3, Senior Vice President, Stimulant Medication, Term Maintenance, Term Safety, Treatment Failure, Treatment Failures, Withdrawal Period

Indianapolis and Tokyo (ots/PRNewswire) – In a Phase II study, Acute Coronary Syndrome (ACS) patients on maintenance clopidogrel/aspirin therapy who were switched to prasugrel (Efient(R) – either 10 mg maintenance dose [MD] or 60 mg loading dose [LD] followed by 10 mg MD) plus aspirin demonstrated a statistically significant greater reduction in Maximal Platelet Aggregation [...]

Continue reading

Acute Coronary Syndrome, Aspirin Therapy, Blood Clots, Clopidogrel, Critical Step, Daiichi Sankyo, Day Seven, Eli Lilly, Eli Lilly And Company, Heart Attack, Lilly And Company, Loading Dose, Maintenance Dose, Maintenance Therapy, Micromolar, Mpa, Platelet Aggregation, Platelet Function, Prasugrel, Prnewswire

Basel, Switzerland, March 19, 2010 (ots/PRNewswire) – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of Tarceva(R) (erlotinib) as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely [...]

Continue reading

Aggressive Disease, Basel Switzerland, Cell Lung Cancer, Chmp, Delay Disease Progression, Erlotinib, Lung Cancer, Lung Cancers, Maintenance Therapy, Maintenance Treatment, Non Small Cell Lung Cancer, Nscl, Nsclc, Otcqx, Prnewswire, Small Cell Lung Cancer, Stable Disease, Switzerland March, Tarceva, Trial 1

Vienna (ots/PRNewswire) – – Treatment With Tiotropium Reduced Lung Function Decline in Younger Patients NOT FOR US MEDIA A new post-hoc analysis of data from the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT(R)) trial presented today at the European Respiratory Society (ERS) Annual Congress demonstrated that tiotropium (SPIRIVA(R)) administered to younger patients (less [...]

Continue reading

Bronchodilator, Chronic Obstructive Pulmonary Disease, Control Group, Copd Patients, Disease Prognosis, European Respiratory Society, Exacerbations, Fev 1, Forced Expiratory Volume, Group Hr, Lung Function, Maintenance Therapy, Obstructive Pulmonary Disease, Patient Population, Post Hoc Analysis, Prnewswire, Spiriva, Term Improvement, Uplift

Basel, Switzerland (ots/PRNewswire) – – For ex-US Media Only – Phase III ATLAS Study Achieves a New Milestone in Treating Advanced Lung Cancer Roche announced today that the Phase III ATLAS study showed patients with advanced non-small cell lung cancer (NSCLC) who received Avastin(R) (bevacizumab) and Tarceva(R) (erlotinib) as combined first-line maintenance treatment had a [...]

Continue reading

Avastin, Basel Switzerland, Bevacizumab, Cell Lung Cancer, Erlotinib, Free Survival, Initial Chemotherapy, Initial Treatment, Line Maintenance, Lung Cancer Patients, Maintenance Therapy, Maintenance Treatment, Non Small Cell Lung Cancer, Nsclc, Prnewswire, Small Cell Lung Cancer, Study Saturn, Survival Time, Tarceva, Time Patients

Basel, Switzerland (ots/PRNewswire) – – For non-US and non-UK Media Only – Long-term Results From a Phase III Study Highlight the Beneficial Role of MabThera in Patients With Recurrent or Resistant Disease Data presented at the 50th Annual Meeting of the American Society of Hematology (ASH) today confirmed that patients with recurrent or resistant follicular [...]

Continue reading

Basel Switzerland, Beneficial Role, Doxorubicin, European Organisation, Free Survival, Group Show, Hodgkin S Lymphoma, Initial Treatment, Lymphoma Patients, Maintenance Therapy, Maintenance Treatment, Marinus, Non Hodgkin S Lymphoma, Prednisolone, Prnewswire, Survival Time, Threefold Increase, University Of Amsterdam, Van Oers, Vincristine

Beerse, Belgium, November 21 (ots/PRNewswire) – Janssen-Cilag announced today that ustekinumab, the first in a new class of biologics, has received a positive opinion for the treatment of moderate to severe plaque psoriasis from the European Committee for Medical Products for Human Use (CHMP). This positive opinion takes patients living with the physical and mental [...]

Continue reading

Beerse Belgium, Biologics, Cardiovascular Events, Contraindication, Controlled Trials, Double Blind Placebo, Endpoint, Janssen Cilag, Maintenance Therapy, Methotrexate, Phase 3, Pivotal Study, Plaque Psoriasis, Prnewswire, Serious Adverse Events, Severe Plaque Psoriasis, Severity Index, Step Closer Towards, Systemic Therapies, Therapeutic Option